Ophthalmic plastic and reconstructive surgery
Incidence of Alemtuzumab-Induced Thyroid-Associated Orbitopathy: A Systematic Review and Meta-Analysis.
Edward Tran, Ali Hadi, Gautham Nair, Lulu L C D Bursztyn, J Alexander Fraser, Edsel B Ing
Published: 202510.1097/IOP.0000000000003017
Abstract
PURPOSE: Alemtuzumab is a monoclonal antibody that targets CD52 and is commonly used to treat multiple sclerosis. Thyroid dysfunction occurs in 20% to 30% of patients treated with alemtuzumab. This may lead to thyroid-associated orbitopathy (TAO), wh…
Preview only. Read the full abstract at the source